Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7396 to 7410 of 7707 results

  1. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Evidence summary
    Published
    24 June 2019

  2. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This guidance has been updated and replaced by NICE diagnostics guidance 60.

    Medtech innovation briefing
    Published
    7 March 2023

  3. Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) (TA869)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1015.

    Technology appraisal guidance
    Published
    16 February 2023

  4. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

    This guidance has been updated and replaced by NICE interventional procedures guidance 794.

    Interventional procedures guidance
    Published
    23 May 2018

  5. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued [GID-TA10961]

    Technology appraisal guidance
    Discontinued

  6. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Technology appraisal guidance
    Published
    26 July 2006

  7. Head injury: assessment and early management (CG176)

    This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).

    Clinical guideline
    Last updated
    13 September 2019

  8. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued [GID-TA10869]

    Technology appraisal guidance
    Discontinued

  9. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development [GID-TA11273] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

    In development [GID-TA10726] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Difficult-to-treat scabies: oral ivermectin (ESUOM29)

    November 2024: This evidence summary has been withdrawn because licensed products are now available.

    Evidence summary
    Published
    18 March 2014

  12. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by NICE interventional procedures guidance 737.

    Interventional procedures guidance
    Published
    30 January 2019

  13. Ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma (IPG605)

    October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.

    Interventional procedures guidance
    Published
    28 February 2018

  14. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Technology appraisal guidance
    Published
    23 August 2000

  15. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Diagnostics guidance
    Published
    2 April 2014